A5070628602- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Ethics in Clinical Research
- Radiopharmaceutical Chemistry and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Cancer, Lipids, and Metabolism
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Bone health and treatments
- Statistical Methods in Clinical Trials
- Cancer Immunotherapy and Biomarkers
- Extracellular vesicles in disease
- Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Chronic Disease Management Strategies
- Cancer-related molecular mechanisms research
- Advanced Radiotherapy Techniques
- Medical Imaging and Pathology Studies
- Immune cells in cancer
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
- Genomics and Rare Diseases
Boston Medical Center
2011-2025
Boston University
2015-2025
Memorial Sloan Kettering Cancer Center
2006-2009
Spanish Oncology Genitourinary Group
2007-2009
Cornell University
2007-2009
Kettering University
2007
Children's Hospital of Philadelphia
2002
University of Pennsylvania
2002
Abstract Purpose: The development of tumor-specific markers to select targeted therapies and assess clinical outcome remains a significant area unmet need. We evaluated the association baseline circulating tumor cell (CTC) number with characteristics survival in patients castrate metastatic disease considered for different hormonal cytotoxic therapies. Experimental Design: CTC were isolated by immunomagnetic capture from 7.5-mL samples blood 120 progressive disease. estimated probability...
Purpose Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered a dose bone-seeking radiopharmaceutical is superior to alone. To build on this strategy and fully integrate repetitively dosed into contemporary regimen, we conducted phase I study docetaxel samarium-153 ( 153 Sm) lexidronam. Patients Methods Men progressive CRMPC were eligible. Cohorts three six defined by escalations as follows: 65, 70, 75, 75 mg/m 2 Sm...
Many patients with prostate cancer are eligible for germline genetic testing, but it is underutilized in clinical practice. We aimed to explore perceptions of and decision making about undergoing testing among cancer. This qualitative interview study enrolled diagnosed who had been treated at a safety-net hospital received referral the previous 12 months. Participants completed an their native language via telephone. Data on use were captured interviews medical record. A thematic analysis...
Introduction The 2018 National Comprehensive Cancer Network guidelines for prostate cancer genetic testing expanded access to services. Few studies have examined how this change has affected provider practice outside of large centers. Methods We conducted a qualitative study multi-disciplinary health care providers treating patients with at safety-net hospital. Participants completed an interview that addressed knowledge, practices, and contextual factors related providing services cancer. A...
Metabolic abnormalities including hyperglycemia and hyperlipidemia have been associated with worse prognosis of prostate cancer (PCa), but there are limited data regarding their impact on the castrate-resistant (CRPC) response novel antiandrogens, namely abiraterone acetate (AA) enzalutamide. Retrospective analysis 61 patients CRPC AA or enzalutamide, treated at Boston Medical Center, was performed. We evaluated hemoglobin A1c (HbA1c), HDL, LDL, Triglycerides BMI within 2months before...
Because of the osseous distribution prostate cancer metastases, progression is more readily identified than response in clinical trials. As a result, there an increased focus on progression-free survival (PFS) as phase 2 endpoint. PFS, however, vulnerable to inter-study design variability. The authors sought identify and quantify this variability resultant error PFS across trials.The reviewed trials cytotoxic agents castration-resistant metastatic over 5 years evaluate policies determining...
Understanding the drivers of delays from diagnosis to treatment can elucidate how reduce time (TTT) in patients with prostate cancer. In addition, available treatments depending on stage cancer vary widely for many reasons. This study investigated relationship TTT and choice sociodemographic factors who underwent external beam radiation therapy (RT), radical prostatectomy (RP), androgen deprivation (ADT), or active surveillance (AS) at a safety-net academic medical center.
With the wide use of prostate specific antigen to detect response and disease progression resistance androgen deprivation is being detected at an increasingly earlier stage. We focused on current management novel investigational strategies for chemonaïve patient population with castration resistant metastatic disease.We reviewed standard hormonal, chemotherapeutic, biological immune based patients cancer who have not yet received taxane chemotherapy.Our understanding natural history this...
Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with multiple metabolic complications, previously predominantly evaluated in the white population. Methods: A chart-based retrospective review was conducted on black patients PCa, considered ADT, from September 2007 to July 2010. Baseline data were collected body mass index (BMI), vitamin-D status, bone mineral density (BMD), dyslipidemia and diabetes. Overweight obesity classified as BMI ≥ 25 30,...
Little is known about the uptake of germline genetic testing for patients with prostate cancer after 2018 guideline changes. This study characterizes service referral patterns and predictors referrals among cancer.A retrospective cohort using electronic health record data was conducted at an urban safety-net hospital. Individuals diagnosed between January 2011 March 2020 were eligible. The primary outcome to services diagnosis. Using multivariable logistic regression, we identified patient...
Enfortumab vedotin (EV) is a novel treatment option for patients with advanced/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two at two different New England tertiary cancer care centers were treated EV while concurrently receiving hemodialysis (HD), where complete response to in both was noted. The use of requiring HD extrapolated from the available pharmacokinetic pharmacodynamic literature on monoclonal antibodies HD. There paucity data...
Abstract Germline genetic testing has been increasingly conducted for treatment implications in patients with prostate cancer due to the expansion of eligibility. Understanding patients' comprehension results is crucial establishing effective result disclosure practices. This importance grown increasing prevalence negative being conveyed via electronic communication and by providers without a genetics specialization. study explores cancer's perceptions communication. We analyzed 24...
5152 Background: Docetaxel (Tax) prolongs survival in patients (pts) with CMPC. Early clinical data suggest that Tax combined bone seeking radiopharmaceuticals may improve relative to chemotherapy alone. 153 Sm-lexidronam (Sam) (Quadramet, Cytogen Inc.) is a radiopharmaceutical short T 1/2 and favorable toxicity profile. Methods: Pts progressive CMPC are treated cohorts of 3–6. Prior treatment taxanes permissible. Cohorts defined by dose escalations of: 65, 70, 75, 75 mg/m 2 Sam 0.5, 0.75, 1...
5076 Background: Blood-based assays are urgently needed to provide molecular information on the specific targets expressed in tumor cells optimize treatment selection. Antibody-capture technologies have been applied isolate circulating (CTC) from small volumes of peripheral blood patients with progressive castrate metastatic prostate cancer. It has demonstrated previously that CTC isolated these represent authentic cancer cells. Methods: CTC, positive for EpCAM (epithelial cellular adhesion...
Abstract Comorbid Type 2 diabetes (T2D), a metabolic complication of obesity, associates with worse cancer outcomes for prostate, breast, head and neck, colorectal several other solid tumors. However, the molecular mechanisms remain poorly understood. Emerging evidence shows that exosomes carry miRNAs in blood encode status originating tissues deliver their cargo to target modulate expression critical genes. Exosomal communication potentially connects abnormal metabolism progression. Here,...
22 Background: Study Purpose: reduce inpatient oncology readmissions; determine if there is a need to standardize trigger for Advance Care Planning in the population. Methods: Investigational Quality Improvement January-June 2014. Retrospective chart review of readmissions on BMC Hematology and Oncology service during 6 month period, 2013 (N = 68). Data abstracted included: demographics (age, race/ethnicity, primary language, education, marital status, ECOG); type stage cancer; consults...
e15082 Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with endocrine complications such as osteoporosis, weight gain, diabetes and dyslipidemia. However, in previous studies, the patient population has been predominantly white. The aim of this study was to examine relevant baseline characteristics, above-mentioned complications, a black presenting consideration ADT. information gained will help us further risk stratify regards possible Methods: A...